2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
This program is top science that showcases hot topics in platelet and megakaryocyte biology. It is balanced between both platelets and megakaryocytes and also a a broad array of topics. Male to Female representation was difficult, but we currently have one woman. Our first alternate is a woman and we suggest having woman moderators (we suggested two junior and two more senior).<br /><br />abs26-7483 was not chosen for an oral presentation due to concerns about lack of key information in the abstract that didn't allow the group to discern the impact of the findings.<br /><br />Backups<br />1. abs26-10358<br />2. abs26-13313<br />3. abs26-1646
Technology and Procedures, Assays, Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Thrombocytopenias, Infectious Diseases, Bacterial, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

471 Platelet 12-lipoxygenase mediates the antiplatelet effects of eicosapentaenoic acid and icosapent ethyl

Krista Anne Goerger, BSc, Ashleigh Kilgore2, Mariane Flores Nascimento, PhD3, Theodore Holman4, Michael Holinstat, PhD5
1 University Of Michigan Medical Center, Ann Arbor, Michigan, United States
2 University Of Michigan Medical Center, Ann Arbor, Michigan, United States
3 University Of Michigan Medical Center, Ann Arbor, Michigan, United States
4 University of California at Santa Cruz, Santa Cruz, California, United States
5 University Of Michigan Medical Center, Ann Arbor, Michigan, United States

The REDUCE-IT trial demonstrated that icosapent ethyl (IPE), an esterified formulation of the omega-3 fatty acid eicosapentaenoic acid (EPA), significantly reduces major adverse cardiovascular events in patients with hypertriglyceridemia and elevated cardiovascular risk. Despite the widespread use of EPA-containing fish oil supplements and the clinical success of IPE, the mechanisms responsible for their cardiovascular protective effects remain incompletely understood. Given the central role of platelet activation in arterial thrombosis, we sought to compare the effects of EPA and IPE on platelet function and determine the mechanisms responsible for their antiplatelet activity.

Using isolated human platelets, we demonstrate that both EPA and IPE significantly inhibit platelet activation. Furthermore, mice administered EPA (50 mg/kg/day) or IPE (50 mg/kg/day) for six weeks exhibited reduced platelet activation, as measured by integrin activation and granule secretion, as well as reduced thrombus formation in vivo. Notably, neither EPA nor IPE significantly prolonged bleeding time. This finding is consistent with the REDUCE-IT trial, which reported no significant increase in bleeding risk with IPE treatment, suggesting preservation of normal hemostatic function despite inhibition of platelet activation. Together, these findings demonstrate that IPE, similar to EPA, directly inhibits platelet activation and thrombotic responses, providing a potential mechanistic explanation for the reduction in ischemic cardiovascular events observed clinically.

To determine the mechanisms responsible for the antiplatelet effects of EPA and IPE, we investigated platelet oxidized lipid products in isolated human platelets and whole blood treated with EPA. Previous studies have suggested that EPA attenuates platelet activation through cyclooxygenase (COX)-1-dependent mechanisms by competing with arachidonic acid (AA), thereby reducing production of prothrombotic AA-derived oxylipins such as thromboxane A2 (TxA2) and 12-hydroxyeicosatetraenoic acid (12-HETE). However, EPA treatment did not alter production of either AA-derived oxylipin. In contrast, EPA resulted in a marked increase in production of 12-hydroxyeicosapentaenoic acid (12-HEPE), the primary 12-lipoxygenase (12-LOX)-derived metabolite of EPA, while EPA-derived COX-1 metabolites remained undetectable. These findings suggest that the antiplatelet effects of EPA are mediated through 12-LOX-dependent pathways rather than alterations in COX-1 metabolism. Consistent with this hypothesis, 12-HEPE directly inhibited platelet activation and demonstrated greater potency than EPA in several assays. Importantly, pharmacologic inhibition of 12-LOX with ML355 significantly reversed the inhibitory effects of EPA while having no effect on the activity of 12-HEPE, demonstrating that EPA-mediated platelet inhibition requires 12-LOX metabolism.

 Collectively, these studies demonstrate that both EPA and IPE inhibit platelet activation and thrombosis while preserving normal hemostatic function. Furthermore, they identify platelet 12-LOX generation of 12-HEPE as a critical mediator of EPA-dependent platelet inhibition and challenge the prevailing hypothesis that EPA exerts its antiplatelet effects primarily through COX-1. By providing mechanistic insight into the antithrombotic effects of EPA and IPE, this work advances our understanding of how omega-3 fatty acids confer cardiovascular protection and highlights the 12-LOX/12-HEPE pathway as a potential therapeutic target for the prevention of thrombotic cardiovascular disease.

Krista Anne Goerger, BSc: No relevant conflicts of interest to declare.